CRANBURY, N.J., Feb. 28,
2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE
American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate the
activity of the melanocortin receptor system, announced that the
United States Patent and Trademark Office issued U.S. Patent No.
11,590,209, titled "Use of Bremelanotide in Patients with
Controlled Hypertension." This issued patent further strengthens
the Company's intellectual property position and coverage for the
Company's approved therapeutic product for hypoactive sexual desire
disorder in premenopausal women, Vyleesi.
The patent has, with patent terms adjustments, a term through
April 29, 2041. The claims of the
patent relate to use of bremelanotide, marketed by the Company
under the trade name Vyleesi, for treatment of female sexual
dysfunction in patients with controlled hypertension. The patent is
solely owned by the Company.
"We are pleased with the issuance of this patent," said
Carl Spana, CEO and President of
Palatin. "The issuance of this patent continues to expand the
breadth and depth of our Vyleesi intellectual property portfolio
and underscores our commitment to innovation in advancing
melanocortin-receptor based therapies."
About Vyleesi® (bremelanotide injection) for Hypoactive
Sexual Desire Disorder (HSDD)
Vyleesi is the first and only as-needed treatment approved by
the FDA for premenopausal women with acquired, generalized
HSDD.
Palatin is actively seeking Vyleesi collaborations for
the United States and for
territories outside the currently licensed territories of
China and Korea. Vyleesi is
licensed to Fosun Pharma in China
and Kwangdong Pharmaceuticals in South
Korea.
Patients and healthcare providers can learn more about HSDD and
Vyleesi at www.vyleesi.com and www.vyleesipro.com.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor systems, with targeted, receptor-specific
product candidates for the treatment of diseases with significant
unmet medical need and commercial potential. Palatin's strategy is
to develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com and follow Palatin on Twitter at
@PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about market potential of
Vyleesi and other Palatin products in development, clinical trial
results, potential actions by regulatory agencies including the
FDA, regulatory plans, development programs, proposed indications
for product candidates, market potential for product candidates,
and potential adverse impacts due to the global COVID-19 pandemic
such as delays in regulatory review, manufacturing and supply chain
interruptions, adverse effects on healthcare systems and disruption
of the global economy, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject to the safe
harbors created thereby. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that could
cause Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, Palatin's ability to
establish and maintain the capability for manufacturing, marketing
and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world,
results of clinical trials, regulatory actions by the FDA and other
regulatory and the need for regulatory approvals, Palatin's ability
to fund development of its technology and establish and
successfully complete clinical trials, the length of time and cost
required to complete clinical trials and submit applications for
regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other factors
discussed in Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-issued-patent-on-vyleesi-bremelanotide-injection-for-hypoactive-sexual-desire-disorder-in-patients-with-controlled-hypertension-301757636.html
SOURCE Palatin Technologies, Inc.